

PROVIDER NOTIFICATION OF RETAIL DRUG POLICY CRITERIA CHANGE			
Drug(s) Impacted	CRITERIA CHANGE	EFFECTIVE DATE	Formulary
Ibrance	Added coverage for HR-positive, HER2-positive locally advanced, recurrent unresectable, or metastatic breast cancer, per FDA label update and NCCN update. Added coverage for use in combination with the new drug Revtorpyk (gedatolisib) for breast cancer, per FDA label.	09/05/2026	Standard Essential
Cavhanza, Danziten, Nilceya, nilotinib, Nilotinib (branded generic), Tasigna	Added Cavhanza to criteria, per FDA approval. For gastrointestinal stromal tumors, required disease to be positive for KIT and/or PDGFRA mutations, per NCCN.	10/21/2026	Standard Metallic Essential